Overview
Find detailed information on selected clinical trials for Retinoblastoma at Cincinnati Children's Hospital Medical Center.
There are two versions of some of the trials. While they contain the same basic information, one version is geared toward healthcare professionals and the other is geared toward families.
| Trials | Healthcare Professionals Versions | Family-Friendly Versions |
|---|
| ADVL0319: A Phase I Study of CC-5013 in Pediatric Patients with Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome |
Professional |
Family-Friendly |
| ADVL0414: A Phase Study of Temozolomide, Oral Irinotecan, and Vincristine for Children with Refractory Solid Tumors |
Professional |
Family-Friendly |
| ADVL0416: A Phase 1 Study of SAHA In Pediatric Patients with Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Followed by a Phase I Study of SAHA in Combination with 13 Cis-Retinoic Acid for Patients with Selected Recurrent/Refractory Solid Tumors |
Professional |
Family-Friendly |
| ADVL0612: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors |
Professional |
Family-Friendly |
| NCI-07-C-0040: A Phase I Trial of the Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients with Refractory Pediatric Solid Tumors |
Professional |
Family-Friendly |
| ADVL0413: Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias |
Professional |
Family-Friendly |
